Heysell SK, Mpagama SG, Nuwagira E, et al. Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial. Lancet Infect Dis 2026; published online Jan 28. https://doi/org/10.1016/S1473-3099(25)00747-9—In this Article, the p value in the Findings in the Summary for patients with microbiologically confirmed tuberculosis in the diagnosis-dependent high-dose group compared with the diagnosis-dependent conventional-dose group should have been 0·079.
Heysell SK, Mpagama SG, Nuwagira E, et al. Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial. Lancet Infect Dis 2026; published online Jan 28. https://doi/org/10.1016/S1473-3099(25)00747-9—In this Article, the p value in the Findings in the Summary for patients with microbiologically confirmed tuberculosis in the diagnosis-dependent high-dose group compared with the diagnosis-dependent conventional-dose group should have been 0·079.